Health Care·Biotechnology·$2.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.20 | N/A | -42.86% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.20 | N/A | -42.86% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about ongoing market conditions affecting performance. They did not provide specific guidance for future quarters.
Management did not provide specific revenue figures or guidance for the upcoming quarters.
The company acknowledged challenges in achieving profitability this quarter.
Veracyte's earnings report indicates a challenging quarter, particularly with a notable EPS miss. The stock reacted negatively, dropping 1.38%, reflecting investor concerns about the company's profitability and lack of guidance. Without clear direction from management, investors may remain cautious in the near term.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
US FOODS HLDG CORP
Nov 8, 2021